ERBB2 and breast carcinoma: As an evolution of the Ab-PROTAC conjugate conceptfor the treatmentof breast cancer, the well-studied 12 was encapsulatedinto Ab conjugate nanoparticles (ACNPs).109 The authors selected poly-lactic acid and polyethylenimine as buildingblocks for the preparation of the nanoparticles, which were loadedwith 12 and conjugated with the anti-HER2 Ab trastuzumabvia a covalent bond (Figure 13).